
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March, 2019**

Commission File Number: **001-38480**

IMV Inc.

(Name of registrant)

130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMV Inc.

Date: March 25, 2019

By: /s/ Pierre Labbé

Name: Pierre Labbé

Title: Chief Financial Officer

Form 6-K Exhibit Index

Exhibit Number	Document Description
99.1	News Release dated March 25, 2019. Presenting at Two Upcoming Investor Conferences.



FOR IMMEDIATE RELEASE

IMV Inc. to Present at Two Upcoming Investor Conferences

Dartmouth, Nova Scotia, March 25, 2019 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that [IMV Chief Executive Officer Frederic Ors](#) will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019.

Details on each conference and presentation are as follows:

- **Venue:** Spring Investor Summit, being held April 1-2, 2019
- **Date of Presentation:** Monday, April 1
- **Time:** 8:30 a.m. ET
- **Location:** JW Marriott Hotel, Essex House, New York City

- **Venue:** HC Wainwright Global Life Sciences Conference, being held April 7-9, 2019
- **Date:** Tuesday, April 9, 2019
- **Time:** 10:40 a.m. BST
- **Location:** Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK

There will be a live webcast of both of these presentations available in the [events, presentations and webcasts section of IMV's website](#). Following the presentations, the webcasts will be archived for 90 days and a copy of the presentations will remain available in the same section of the website.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

###

Source: IMV Inc.

Investor Relations:

Marc Jasmin, IMV Senior Director, Investor Relations and Communications

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E: mjasmin@imv-inc.com

Media:

Andrea Cohen, Sam Brown Inc.

T: (917) 209-7163 E: andreacohen@sambrown.com
